Aayush Wellness Limited Overview
Aayush Wellness Limited is a BSE/MSEI-listed Indian micro-cap. Since 2023–24 it has repositioned itself from a dormant rice-trading shell, the former Aayush Food and Herbs Limited, into what management calls an "integrated healthcare and preventive wellness company". Its revenue base was effectively nil in FY2024. It reached ₹73 crore in FY2025 and ₹155 crore in FY2026, and stood at ₹166 crore on a trailing basis by June 2026. Operating margins, however, are only 1–2%, a profile closer to distribution or trading than to branded consumer health. The product portfolio is herbal and nutraceutical: herbal pan masala, gummies, and condition-specific Ayurvedic tablets for immunity, liver, diabetes, lung and calcium. Around it, the company has layered stated ambitions in diagnostics (Aayush Labs), smart health kiosks, tele-consultation, wellness tourism and Southeast Asian exports through a Singapore subsidiary. The company has no promoter, a concentrated non-institutional shareholder base, and has changed auditors repeatedly. The equity has fallen about 90% from its July 2025 peak.
The company's own description
The company's recent filings and press releases describe Aayush Wellness as an integrated healthcare company. They say it focuses on preventive healthcare, nutraceuticals, wellness supplements and condition-specific healthcare products, and that it is building a "scalable healthcare and wellness ecosystem". The company also says it holds ISO 9000 and ISO 22000 certifications. The FY2023–24 Annual Report presents a vision of a "healthier, happier India" with products that "bridge nutritional gaps". Screener's summary of the FY2024 Annual Report says the company describes an integrated platform offering online doctor consultations, nutritional support programmes and health-awareness campaigns. Third-party profiles (S&P Global via Simply Wall St) describe a business spanning development, production, marketing and distribution of health and wellness products under the "Aayush" brand.
Earlier self-descriptions are materially different, and the change is important context:
FY2016–FY2023 (Aayush Food and Herbs): a trader of basmati and non-basmati rice, selling in India and exporting, mainly to the Gulf and West Africa. Rice trading and export began in the last quarter of FY2015–16.
Late 2024: "India's smart nutrition company" (November 2024 and January 2025 press releases).
2025–2026: "integrated healthcare company" and "preventive healthcare company".
Independent characterisation
Judged by its financial statements, Aayush Wellness is today a low-margin consumer health and nutraceutical trading and distribution business with an aspirational healthcare-services layer:
-
Revenue scale vs. margin profile. FY2026 consolidated revenue was ₹155.5 crore against operating profit (EBITDA) of only about ₹1.8 crore, an operating margin of about 1.2%. TTM gross profit is reported at about ₹5.4 crore (₹54.0 million) on ₹170 crore revenue (Simply Wall St, S&P data), a gross margin of about 3%. Branded nutraceutical companies typically report gross margins of 40–70%. A 3% gross margin points to traded or contract-manufactured volume, or institutional and export bulk sales, rather than branded retail at full margin.
-
Working-capital profile. Debtor days are about 0, inventory days about 2 and payable days about 1 (Screener, FY2026). This is unusual for an FMCG or nutraceutical brand, which would normally carry channel receivables and inventory. It looks more like back-to-back trading.
-
Asset-light. Fixed assets are effectively zero (rounded to ₹0 crore in FY2024–FY2026) and depreciation is ₹0.01 crore per quarter. No owned manufacturing plant is disclosed. Products are presumably made by third-party (loan-licence or contract) manufacturers. This is not confirmed in filings reviewed.
-
Earnings composition. In FY2026, other income of about ₹2.6 crore (₹0.65 crore in each of the four quarters, and again in Q1 FY2027) made up roughly 59% of profit before tax (about ₹4.4 crore). The core operating business contributed only about ₹1.8 crore.
Business model and revenue model
| Revenue stream | Model | Disclosure status |
|---|---|---|
| Branded herbal/nutraceutical products (pan masala, gummies, tablets, capsules) | Product sales, B2C via e-commerce (own online platform, Flipkart, Blinkit) and offline distribution | Launched; revenue split not disclosed |
| Export of nutraceuticals (Singapore: effervescent tablets, marine collagen, probiotics, super-greens powders) | B2B product supply to distributor (Cosmos Holdings Pte Ltd) | US$3 million order announced Dec 2024, deliverable over about 12 months; recognised revenue not disclosed |
| Healthcare services: Aayush Health Centre (Virar), Smart Health ATMs/kiosks, tele-consultation, diagnostics (Aayush Labs), genome testing | Service and fee-based; intended recurring revenue | Announced 2025; revenue contribution not disclosed, likely immaterial |
| Wellness tourism (retreats) | Service/experience | Announced Dec 2024; no evidence of operating revenue |
| Startup accelerator / investment corpus (₹5 crore) | Strategic investment | Announced 2025; Healthrashi collaboration is the only named deal |
Product vs. service vs. subscription vs. licensing mix: not publicly disclosed. Based on the margin and asset profile, product sales almost certainly account for all or nearly all revenue. There is no evidence of subscription or licensing revenue.
Value-chain position
Aayush sits in the brand-owner / marketer / distributor layer. It outsources formulation manufacturing (inferred from negligible fixed assets), and sells through third-party digital marketplaces, quick commerce and export distributors. It does not appear to own raw-material sourcing, manufacturing, or retail infrastructure, apart from the single Virar health centre.
Customer types and end-markets
| Customer type | End-market |
|---|---|
| Urban retail consumers (e-commerce, quick commerce) | Indian nutraceuticals / dietary supplements; herbal mouth fresheners (pan masala substitute) |
| Export distributors | Singapore / ASEAN health supplements |
| Patients and local communities (Virar health centre, kiosks) | Primary preventive care, diagnostics, tele-medicine |
| Government health programmes (stated intention) | Public preventive health (e-Sanjeevani-style telemedicine) |
Strategy
Stated strategy themes (paraphrased from FY2024–FY2026 filings and press releases)
-
Preventive healthcare positioning. The company aims to be an integrated preventive-healthcare and wellness platform rather than a single-product company.
-
Portfolio breadth in condition-specific nutraceuticals. It is launching roughly one new SKU every 1–3 months across sleep, beauty, cognition, immunity, liver, metabolic, respiratory and bone health.
-
Omnichannel distribution. Own D2C platform, marketplaces (Flipkart), quick commerce (Blinkit), offline, and exports.
-
Healthcare services and digital health. Smart health kiosks, the Virar health centre, tele-consultation, diagnostics (Aayush Labs) and genome testing.
-
Internationalisation. Singapore hub for ASEAN and the export subsidiary in India.
-
Ecosystem investing. A ₹5 crore startup accelerator / investment corpus.
-
Ayurveda-plus-science branding. Ancient Ayurvedic principles combined with modern formulation.
Initiative register (last 24 months)
| Date | Initiative | Type | Quantified target | Status |
|---|---|---|---|---|
| Jul 2024 | Online platform | Channel | — | Live |
| Jun 2024 | ESOP 2024 | Talent | Pool size not captured | Grants approved 7 Jan 2026 |
| Dec 2024 | Wellness tourism | New business | — | No evidence of execution |
| Early 2025 | ₹5 crore (₹50 million) startup/investment corpus | Investment | ₹5 crore | One collaboration (Healthrashi) |
| Apr 2025 | Diagnostics via genome testing | New business | — | Aayush Labs launched Sep 2025 |
| Apr 2025 | Virar health centre / Smart Health ATM | Services | National roll-out | One site disclosed |
| Jun 2025 | Smart Health Kiosks and Medical Support Centres | Capex plan | Up to ₹25 crore initial phase | No capex visible in FY2026 cash flow (capex ≈ 0) |
| Jun–Sep 2025 | Singapore subsidiary | International | SGD 10,000 seed | Incorporated |
| Sep 2025 | Healthrashi collaboration | Partnership / sourcing | — | Signed |
| Nov 2025 | Blinkit partnership | Channel | — | Live |
| Dec 2025 – Oct 2026 | Five new tablet launches | Product | — | Launched |
| Jun 2026 | Herbal masala push in Maharashtra post-MCOCA gutkha crackdown | Market opportunity | — | Messaging only |
ESG commitments
None disclosed.
Cost programmes
None disclosed.
Medium-term guidance
Not publicly disclosed. No revenue, margin or EPS guidance was found. The ScanX coverage of Q1 FY2027 explicitly notes the absence of management guidance. Third-party commentary (Sahi, Aug 2026) lists OPM sustainably above 5% and net margin above 4.5% as monitorables. These are analyst framings, not company targets.
Analyst observation. The ₹25 crore kiosk plan is about twice the company's FY2026 net worth (about ₹12 crore). FY2026 cash flows show no capex and only about ₹5 crore of new borrowings. Funding for the stated healthcare-services ambitions is therefore unclear, and execution should be presumed slow or partial until capex appears in reported cash flows.
Products & Services
Consumer products (branded "Aayush")
| # | Product | Launch date | Description / key ingredients (as disclosed) | Target customer | Pricing |
|---|---|---|---|---|---|
| 1 | Aayush Herbal Pan Masala | Jun 2024 (BSE intimation); listed on Flipkart (2024) | Herbal mouth freshener positioned as a tobacco-free, Ayurveda-inspired alternative to gutkha/pan masala; company links it to "tobacco de-addiction" | Adult consumers of mouth fresheners / pan masala, especially in Maharashtra (company press release, Jun 2026) | — |
| 2 | Dreamy Sleep Gummies | FY2025 | Gummy supplement to support sleep and relaxation | Urban adults with sleep issues | — |
| 3 | Beauty Vitamin Gummies | FY2025 | Gummy supplement for skin, hair and nails | Urban adults (beauty-from-within) | — |
| 4 | Brain Fuel Capsules | 11 Jul 2025 | Herbal cognitive-support blend: Brahmi (Bacopa monnieri), Ashwagandha, Ginkgo biloba, Turmeric/curcumin, Gotu Kola (Centella asiatica) | Students, professionals, elderly | — |
| 5 | Immunity Booster Tablets | 8 Dec 2025 | Blend of traditional and science-backed ingredients to support the body's natural defences (formula not itemised in sources) | General population; seasonal demand | — |
| 6 | Liver Care / Liver Detox Tablets | 24 Apr 2026 | Herbal formulation for liver detoxification, protection and regeneration | Lifestyle-disease-affected adults | — |
| 7 | Aayush Dia Shield Tablets | 8 May 2026 | Preventive/supportive product for long-term blood-sugar management; company frames entry into a ₹366.56 billion metabolic-health market | Pre-diabetic / diabetic adults | — |
| 8 | Lung Care Tablets | 29 Aug 2026 | Respiratory-wellness formulation; company cites an ₹18,913 crore respiratory market | Urban adults exposed to pollution; respiratory wellness | — |
| 9 | Aayush Calcium Vitamin Tablets | 16 Oct 2026 | Calcium and vitamin supplement (bone health) | Women, elderly, general | — |
Export / B2B nutraceutical lines (Cosmos Holdings order, Dec 2024)
The company's disclosure names four categories: effervescent tablets, marine collagen, probiotics, and super-greens powders ("and more"). Delivery was to run over about one year. Branding (Aayush vs. private label) is not disclosed.
Healthcare services
| # | Service | Launch | Description | Status |
|---|---|---|---|---|
| 1 | Online health/wellness platform | 3 Jul 2024 | E-commerce and digital access to products; online doctor consultations, nutrition programmes (per FY2024 AR summary) | Operating |
| 2 | Aayush Health Centre, Virar (Mumbai) with Smart Health ATM ("Cloud Clinic") | 26 Apr 2025 | Kiosk-based quick diagnostics and telemedicine, modelled on the Health Ministry's e-Sanjeevani service; also mental-wellness programmes | One centre disclosed; national scale-up planned |
| 3 | Smart Health Kiosks & Medical Support Centres | Plan announced Jun 2025 | Up to ₹25 crore investment in the initial phase | Execution status not disclosed |
| 4 | Genome-testing-led diagnostics | Announced 15 Apr 2025 | Entry into diagnostics via genome testing | Status not disclosed |
| 5 | Tele-consultation and diagnostic testing | Announced 21 Jun 2025 | Foray into tele-medicine and diagnostics | Status not disclosed |
| 6 | Aayush Labs | 3 Sep 2025 | Diagnostics brand positioned as accessible, affordable and patient-first | Launched; revenue not disclosed |
| 7 | Healthrashi-sourced equipment (AI health kiosks, mobile clinics, automated diagnostic platforms, healthcare vending machines) | 22–23 Sep 2025 | Deployed under Aayush's own brand | Status not disclosed |
| 8 | Wellness tourism retreats | Announced 23 Dec 2024 | Retreats with nutritional counselling, workshops and Ayurveda therapies; partnerships with tourism boards contemplated | No operating evidence |
Distribution channels
Own e-commerce site (Jul 2024), Flipkart (pan masala), Blinkit quick commerce (Nov 2025), offline distribution (not detailed), export distributor (Cosmos Holdings Pte Ltd, Singapore).
Financial Narrative
Income statement (INR crore)
Sources and reconciliation:
-
FY2022–FY2023 revenue, expenses and operating profit come from the Screener standalone history (BSE data). PAT for these years is not reliably extractable from the sources reviewed. Screener showed negative ROE (about -9% to -12%) for the period, implying losses.
-
FY2024 is Screener consolidated: sales ₹0.60 crore, OPM 58%, PAT ₹0.57 crore, EPS ₹0.12. Angel One cites FY2024 revenue of ₹0.84 crore (probably total income) and EPS of ₹0.176 (probably not bonus-adjusted). Both are noted.
-
FY2025 revenue of ₹73.39 crore and PAT of ₹3.37 crore are from Angel One's coverage of the FY2025 results. Business Guardian (Jun 2025) cites income from operations of ₹73.34 crore and net profit of ₹3.05 crore (+434%), possibly standalone or a different line. Quarterly consolidated PAT sums to ₹3.35 crore. FY2025 EBITDA is the sum of quarterly operating profit (0.24 + 0.92 + 1.09 + 1.19); Screener's annual OPM is 4.5%.
-
FY2026 revenue from operations of ₹155.48 crore (+112%) is from the company press release (Tribune/ANI, 2 Jun 2026). EBITDA, other income, PBT and PAT are sums of the four FY2026 quarters on Screener (EBITDA 0.51 + 0.56 + 0.41 + 0.35; other income 0.65 × 4; PBT 1.15 + 1.20 + 1.05 + 0.99; PAT 1.16 + 1.21 + 1.05 + 0.56). Annual EPS is ₹0.82.
-
The FY2025 dividend was an interim of ₹0.01 per share. The ₹0.025 per share appears in the FY2025 Directors' Report and is consistent with Screener's 3% FY2026 payout. Timing of declaration (final FY2025 vs. FY2026) should be confirmed against the FY2026 Annual Report.
Margin analysis (%)
The FY2026 gross margin is a TTM proxy: Simply Wall St (S&P) gross profit of ₹54.0 million on revenue of ₹1.7 billion. Annual gross profit is not separately disclosed in the sources reviewed. FY2024 margins are meaningless because the revenue base was only ₹0.6 crore.
Growth
5-year revenue CAGR (FY2021 to FY2026): FY2021 standalone revenue was ₹151.58 crore (rice trading) and FY2026 was ₹155.48 crore. The CAGR is about 0.5%. After a near-total collapse and rebuild, the company's revenue is only now back to its FY2021 level.
2-year CAGR (FY2024 to FY2026): about 1,510% p.a. This is mathematically correct but analytically meaningless given the base.
Quarterly trend (consolidated, INR crore)
Source: Screener.in consolidated quarterly results (BSE filings). Business Standard reports a Q1 FY2027 OPM of 2.36% against Screener's 2.33%.
Key reading of the quarterly data:
-
Margin compression as revenue scaled. OPM peaked at 6.4% in Q2 FY2025 and fell steadily to 0.7% by Q4 FY2026, even as quarterly revenue more than tripled. That is the opposite of the operating leverage expected from a brand-building business. It suggests incremental revenue came from very low-margin traded or bulk volume.
-
Other income propped up profit. From Q1 FY2026 a constant ₹0.65 crore per quarter appeared and kept PBT flat at about ₹1.0–1.2 crore while core operating profit halved. The source of this income (interest on inter-corporate deposits, treasury income, or other) is not disclosed in the sources reviewed and is a priority diligence item. Screener flags that earnings include ₹2.60 crore of other income and that the company "might be capitalising interest cost".
-
Q4 FY2026 tax charge. An effective tax rate of 43% cut Q4 PAT to ₹0.56 crore (down 49% YoY). The rate was about 0% in the other quarters (low tax rate flagged by Screener). That suggests a catch-up provision or the use of carry-forward losses.
-
Q1 FY2027 sequential decline. Revenue fell 32% QoQ (₹48.4 crore to ₹33.1 crore) even though it grew 46% YoY. This breaks the sequential growth run of FY2026.
Balance sheet (consolidated, INR crore; FY2022–FY2023 standalone where available)
Source: Screener consolidated balance sheet (rounded to nearest crore). Book value per share is ₹2.52 (Oct 2026), so FY2026 equity is about ₹12.3 crore.
Short-term vs. long-term debt split: not disclosed in the sources reviewed. MarketInOut reports debt/equity of 0.39 (consistent with about ₹5 crore of borrowings on about ₹12 crore of equity).
Cash and equivalents / net debt: not disclosed in the sources reviewed. FY2026 net cash flow was about +₹2 crore, so cash is likely low single-digit crore.
Working capital: Screener working-capital days were about 0 in FY2026 (268 in FY2024, 3 in FY2025).
Capital raising: paid-up capital rose from about ₹3 crore to about ₹5 crore between FY2024 and FY2025, mainly from the 1:2 bonus (capitalised from reserves) after the split. A planned rights issue (promoter named by IPO Central as Pallavi Mittal) was reported in Dec 2024. No completed rights issue was found.
Cash flow (consolidated, INR crore)
Source: Screener consolidated cash flows. Dividends paid round to ₹0 crore (₹0.01 per share × 4.87 crore shares ≈ ₹0.05 crore).
-
In FY2026, borrowings rose by about ₹5 crore but financing cash flow rounds to ₹0. The rounding or classification should be checked against the audited cash-flow statement in the FY2026 Annual Report.
-
Cumulative FY2024–FY2026 operating cash flow was negative while cumulative reported PAT was about ₹7.9 crore. Earnings are not converting to cash.
Key ratios
Sources: Screener ratios (ROCE, debtor/inventory/payable days, CCC; ROE latest 38.8%; 3-year average ROE 36.4%). MarketInOut TTM as of Jul 2026 (ROA 28.20, ROIC 13.19, ROE 38.29, interest cover 277, D/E 0.39). Asset turnover is computed as revenue ÷ total assets. The current ratio is not disclosed. Net debt/EBITDA cannot be computed without a cash figure.
Commentary. The high ROE and ROCE are arithmetic results of a tiny equity base (about ₹12 crore) and of other income. They do not show a strong franchise. Strip out other income and FY2026 core pre-tax return on equity falls to roughly 15%. The asset-turnover ratio of about 8.6x is typical of commodity trading, not of nutraceutical brand-building.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (implied) | Contents | Revenue 3-yr | Status |
|---|---|---|---|
Wellness and nutraceutical products | Pan masala, gummies, tablets, capsules | — | Operating |
Exports | Singapore nutraceutical supply (Cosmos order) via parent / Aayush Worldwide / Aayush International | — | Operating (order-based) |
Healthcare services | Health centre, kiosks, tele-consult, diagnostics (Aayush Labs) | — | Early stage |
Wellness tourism | Retreats | Nil evident | Announced only |
“—” = not publicly disclosed.
Revenue by Segment
| Metric (INR Cr) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Consolidated revenue from operations | 22.63 | 33.11 |
Standalone revenue from operations | 22.63 | 24.72 |
Implied subsidiary revenue | 0 | 8.39 |
Consolidated PAT | 1.16 | 1.42 |
Standalone PAT | 1.16 | 1.20 |
Implied subsidiary PAT | 0 | 0.22 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Relationship | Jurisdiction | Incorporated | Stated purpose |
|---|---|---|---|---|
Aayush Wellness Limited | Listed parent | India (Maharashtra since Dec 2025) | 1984 | Holding / operating company |
Aayush Healthsciences Private Limited | WOS | India | 7 Nov 2024 | Healthcare / health sciences (scope not detailed) |
Aayush Worldwide Private Limited (CIN U46497MH2025PTC437587) | WOS | India (Maharashtra) | Jan 2025 (press release 7 Jan 2025; Directors' Report shows "Jan 04, 2024", likely a typographical error given the 2025 CIN year code) | Export of herbal and nutraceutical products |
Aayush Labs Private Limited | WOS | India | 26 Aug 2025 | Diagnostics |
Aayush Ventures Private Limited | WOS | India | 27 Aug 2025 | Investment / startup accelerator vehicle (inferred) |
Aayush International Pte. Ltd. | WOS | Singapore | 26 Sep 2025 | ASEAN regional base; initial capital SGD 10,000 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 17.37 | 8.10 | 0.60 | 73.39 | 155.48 |
Total expenses (ex-dep, interest) | 19.30 | 8.91 | 0.25 | 70.10 | 153.65 |
Operating profit / EBITDA | -1.93 | -0.81 | 0.35 | 3.44 | 1.83 |
Other income | — | — | 0.24 | 0.02 | 2.60 |
Interest expense | — | — | 0.00 | 0.10 | 0.00 |
Depreciation | — | — | 0.00 | 0.00 | 0.04 |
Profit before tax | — | — | 0.59 | 3.38 | 4.39 |
Tax rate (%) | — | — | 3.39 | 0.00 | 10.00 |
Net profit (PAT) | — | — | 0.57 | 3.37 | 3.98 |
EPS basic (INR, split/bonus adjusted) | — | — | 0.12 | 0.69 | 0.82 |
Dividend per share (INR) | 0 | 0 | 0 | 0.01 | 0.025 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | — | — | — | — | 3.2 |
EBITDA / operating margin | -11.1 | -10.0 | 58.3 | 4.7 | 1.2 |
PBT margin | — | — | 98.3 | 4.6 | 2.8 |
Net margin | — | — | 95.0 | 4.6 | 2.6 |
Other income as % of PBT | — | — | 40.7 | 0.6 | 59.2 |
Growth metric (%)
| Growth metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | -88.5 | -53.4 | -92.6 | 12,132 | 111.9 |
PAT growth YoY | — | — | — | 491 | 18.1 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric (INR Cr) | Q1FY2025 | Q2FY2025 | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|---|---|---|---|
Sales | 11.08 | 14.28 | 25.63 | 22.35 | 22.63 | 39.91 | 44.53 | 48.41 | 33.11 |
Operating profit | 0.24 | 0.92 | 1.09 | 1.19 | 0.51 | 0.56 | 0.41 | 0.35 | 0.77 |
OPM (%) | 2.17 | 6.44 | 4.25 | 5.32 | 2.25 | 1.40 | 0.92 | 0.72 | 2.33 |
Other income | 0.02 | 0.00 | 0.00 | 0.02 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 |
PBT | 0.26 | 0.92 | 1.09 | 1.11 | 1.15 | 1.20 | 1.05 | 0.99 | 1.41 |
Net profit | 0.25 | 0.92 | 1.09 | 1.09 | 1.16 | 1.21 | 1.05 | 0.56 | 1.42 |
EPS (INR) | 0.05 | 0.19 | 0.22 | 0.22 | 0.24 | 0.25 | 0.22 | 0.12 | 0.29 |
Balance Sheet
| Metric (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Equity share capital | 3 | 5 | 5 |
Reserves | 2 | 3 | 7 |
Total equity | 5 | 8 | 12 |
Borrowings (total) | 0 | 0 | 5 |
Other liabilities | 0 | 0 | 1 |
Total liabilities and equity | 5 | 9 | 18 |
Fixed assets | 0 | 0 | 0 |
Investments | 0 | 0 | 0 |
Other assets (current) | 5 | 8 | 17 |
Goodwill and intangibles | 0 | 0 | 0 |
Cash Flow and Margin Analysis (%)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities | — | — | -1 | 0 | -1 |
Cash from investing activities | — | — | 0 | 0 | 3 |
Cash from financing activities | — | — | 0 | 0 | 0 |
Net cash flow | — | — | -1 | 0 | 2 |
Capex | — | — | 0 | 0 | 0 |
Free cash flow | — | — | -1 | 0 | -1 |
Dividends paid | — | — | 0 | 0 | 0 |
Buybacks | 0 | 0 | 0 | 0 | 0 |
CFO / EBITDA (%) | — | — | -160 | 11 | -17 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE (%) | — | 38.8 | 38.8 |
ROCE (%) | — | 51 | 35 |
ROA (%) | — | — | 28.2 |
ROIC (%) | — | — | 13.2 |
Debt / equity (x) | 0 | 0 | 0.39 |
Interest coverage (x) | — | — | 277 |
Asset turnover (x) | 0.12 | 8.2 | 8.6 |
Debtor days | 12 | 1 | 0 |
Inventory days | — | 1 | 2 |
Payable days | — | 1 | 1 |
Cash conversion cycle (days) | 12 | 1 | 1 |
Revenue by Region
| Region (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue | 0.60 | 73.39 | 155.48 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Last close | ₹25.30 | Screener, 16 Oct 2026 |
1-year return | -57% (Screener); -62% to -71% (Anand Rathi, Aug–Sep 2026 snapshots) | Varies with look-back date |
3-year price CAGR | 125% (Screener); about 1,240–1,258% cumulative 3-year return (Anand Rathi) | Oct 2026 / Aug–Sep 2026 |
5-year price CAGR | 68% | Screener |
10-year price CAGR | 34% | Screener |
All-time high (split/bonus adjusted) | ₹267.30 on 18 Jul 2025 | Accord Fintech |
Drawdown from ATH | About -90.5% | Computed |
52-week range | ₹21.20 – ₹66.90 | Screener, Oct 2026 |
BSE group | X | Accord Fintech |
Liquidity | BSE volume about 47,000–58,000 shares on sample days (2026) | Finology; MarketsMojo |
Share Price
| Metric | Jan2025 | Jun2025 | Jul2025 | Nov2025 | Mar2026 | Jun2026 | Oct2026 |
|---|---|---|---|---|---|---|---|
Share price (INR) | 120.05 | 136.95 | 267.30 | 35.88 | 34.25 | 28.78 | 25.30 |
Valuation Multiples
| Multiple | Aayush Wellness | Source |
|---|---|---|
P/E (TTM) | 29.0x | Screener, Oct 2026 |
P/B | 10.0x | Screener, Oct 2026 (Value Research 8.6x on 1 Oct 2026) |
EV/EBITDA | 26.2x | MarketInOut, Jul 2026 |
EV/Sales | 0.75x | MarketInOut, Jul 2026 |
Market cap / sales | About 0.74x | Computed (₹123 crore / ₹166 crore) |
Dividend yield | 0.10% | Screener |
Valuation Multiples (Annual)
| Multiple | Jan2025 | Mar2026 | Oct2026 |
|---|---|---|---|
P/E (x) | 99.9 | 81.3 | 29.0 |
P/B (x) | 11.6 | 33.0 | 10.0 |
Dividend History
| Fiscal year | Dividend per share (INR) | Type | Payout (%) |
|---|---|---|---|
FY2025 | 0.01 | Interim (first ever) | 1 |
FY2026 | 0.025 | Per FY2025 Directors' Report; timing to be confirmed | 3 |
Action by Date
| Date | Action |
|---|---|
19 Jun 2024 | 10-for-1 split (FV ₹10 → ₹1) |
29 Oct 2024 | 1:2 bonus (1 bonus share per 2 held) |
2024 / Jan 2026 | ESOP 2024 instituted; first grants approved 7 Jan 2026 |
Dec 2024 (reported) | Rights issue proposal; not completed |
Analyst Conclusions
Management guidance
None issued. The FY2026 results press release (Jun 2026) set out qualitative intent: continued expansion across preventive healthcare, nutraceuticals, wellness supplements and digital health ecosystems. It gave no numerical targets.
Consensus expectations
Not available (no coverage). Simple run-rate arithmetic: Q1 FY2027 revenue of ₹33.1 crore annualises to about ₹132 crore, below FY2026's ₹155.5 crore. Matching FY2026 therefore requires a sequential rebound. TTM revenue at June 2026 was ₹166 crore.
Bull case
-
Distribution flywheel. Blinkit plus marketplaces plus exports have doubled revenue for two years running (FY2025 to FY2026 +112%; Q1 FY2027 +46% YoY). With nine SKUs, a pivot toward higher-margin branded retail could lift OPM toward 5%+. Q1 FY2027 OPM already recovered to 2.3% from 0.7% in Q4 FY2026.
-
International subsidiaries scaling. Subsidiary revenue rose from nil to about ₹8.4 crore in Q1 FY2027 at a positive margin. A Singapore hub could make exports a meaningful, possibly higher-margin, leg.
-
Optionality at a low valuation in absolute terms. At about ₹123 crore market cap and about 0.75x EV/Sales, the market assigns little value to the healthcare-services options (Aayush Labs, kiosks via Healthrashi). Any visible, funded roll-out could re-rate the shares.
Bear case
-
Revenue quality is questionable. A gross margin of about 3%, near-zero receivable and inventory days, and negative operating cash flow look like pass-through trading, not a consumer-health franchise. Reported "growth" may carry little economic value.
-
Governance red flags are cumulative. No promoter, a cluster of LLPs selling down, two auditor exits in six months, a Beneish M-score above the risk threshold, unexplained flat other income supplying about 59% of PBT, and a 56-session upper-circuit run followed by a roughly 90% collapse. These match patterns that SEBI and the exchanges have historically scrutinised in micro-caps.
-
Ambition-capital mismatch. Stated initiatives (₹25 crore kiosks, diagnostics, tourism, accelerator) far exceed a net worth of about ₹12 crore and negative free cash flow. The depressed share price and abandoned rights issue limit funding, so execution risk and dilution risk are both high.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Q2 FY2027 results (due by mid-Nov 2026) | Tests whether the Q1 sequential decline was temporary; OPM trajectory |
| Disclosure of the source of other income (₹0.65 crore per quarter) | Earnings-quality clarity |
| FY2026 Annual Report: auditor's report, CARO, related-party transactions, KMP remuneration, contingent liabilities | Key governance diligence; any qualification or emphasis-of-matter |
| Postal ballot results (Aug 2026) and AGM outcome (Sep 2026) | Shareholder support for new auditor and directors |
| Standalone vs. consolidated revenue split each quarter | Whether the parent's brand business is growing (only +9% YoY in Q1 FY2027) |
| Capex / kiosk deployment evidence in cash-flow statements | Validates the healthcare-services strategy |
| Funding actions (rights issue, preferential allotment, ESOP dilution) | Dilution risk |
| Exchange surveillance (ASM/GSM) status and any SEBI/BSE actions | Regulatory risk |
| Changes in top-holder stakes (Skybridge Incap, Avance Ventures, V Cats) | Continued distribution or stabilisation |
| Regulatory developments in nutraceutical claims and pan masala | Category risk |
Analyst verdict
Aayush Wellness Limited is the corporate successor to Aayush Food and Herbs Limited. Within three years it has turned a dormant rice-trading shell into a company reporting ₹155 crore of FY2026 revenue and consistent, if small, quarterly profits. Measured by the top line, the pivot looks dramatic: FY2025 revenue rose more than a hundredfold and FY2026 doubled again. A portfolio of Ayurvedic and nutraceutical SKUs, quick-commerce and export channels, and a Singapore subsidiary give the "integrated preventive-healthcare" story a surface coherence.
The underlying financial statements tell a less flattering story. Gross margin of about 3% and operating margin of about 1% are commodity-trading economics. Working-capital days near zero and negative operating cash flow point to pass-through volume rather than a consumer brand with pricing power. More than half of FY2026 pre-tax profit came from a perfectly flat, undisclosed other-income stream. Most of Q1 FY2027's growth came from newly formed subsidiaries rather than the parent's branded business, which grew only 9%.
Governance is the decisive weakness. There has been no promoter since December 2023. Ownership is concentrated in LLPs that have been net sellers to a fast-growing retail base. The company lost two statutory auditors within six months. The stock ran up through more than fifty consecutive upper circuits before collapsing about 90%. No institution owns the shares and no analyst covers them.
On balance, Aayush Wellness should be treated as a high-risk, speculative micro-cap whose reported growth has not yet been validated by margins, cash generation or governance quality. The healthcare-services narrative remains largely unfunded. A constructive stance would require four things: (i) clean FY2026 audit opinions, (ii) transparent disclosure of other income and related-party flows, (iii) sustained operating margins above 5% with positive operating cash flow, and (iv) institutional or credible strategic ownership. Until then, the burden of proof rests firmly with the company.
End of dossier. All figures in INR unless stated. "Not publicly disclosed" means the data point was not found in company filings or reliable secondary sources reviewed as of 18 October 2026. Third-party data (Screener/C-MOTS, S&P via Simply Wall St, MarketInOut, Value Research, Tijori) may differ from audited filings because of rounding, classification and update timing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / notes | Age | FY compensation |
|---|---|---|---|---|---|
Naveenakumar (Naveena Kumar) Kunjaru (DIN 07087891) | Managing Director & Chairman | MD since 12 Jun 2023; Chairman since 13 Jun 2023 | Signs essentially all exchange filings and press releases; public face of the turnaround. Prior roles and education not disclosed in sources reviewed. | About 45 (Simply Wall St, 2025) | Not disclosed in sources reviewed (Simply Wall St: "no data") |
Surajmal Jain | Chief Financial Officer | About 2024 onward (tenure about 1.2 years as of May 2025, Simply Wall St) | — | — | — |
Sneha Khemka | Company Secretary & Compliance Officer | Appointed 2024–25 (under 1 year as of May 2025) | — | — | — |
Akshay Vijay Nawale | Former CFO | Listed in FY2023 Annual Report | Departure date not disclosed | — | — |
Urmi Haresh Shah | Former Company Secretary | Listed in FY2023 Annual Report | Departure date not disclosed | — | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Category | Appointed | Notes |
|---|---|---|---|
Naveenakumar Kunjaru | Executive, MD & Chairman | Jun 2023 | Combined Chair/MD role |
Kashiram Jadhav (DIN 11640980) | Additional Non-Executive Non-Independent Director | 31 Mar 2026 | Regularisation sought via postal ballot (Jul–Aug 2026) |
Second additional director (name not captured in sources reviewed) | Additional Non-Executive Non-Independent Director | 31 Mar 2026 | Regularisation sought via postal ballot |
Independent directors (names not captured in sources reviewed) | Non-Executive Independent | Appointments of 30 May 2023 and 27 Jun 2023 noted in FY2023 AGM notice | Committee memberships not captured |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
12–13 Jun 2023 | N. Kunjaru appointed MD and Chairman | Coincides with exit of promoter group and business pivot |
May–Jun 2023 | Independent directors appointed | Board reconstitution |
2023–2025 | CFO change (Nawale → Jain); CS change (Shah → Khemka) | Not explained in sources |
31 Mar 2026 | Two non-independent non-executive additional directors | No stated rationale; regularised via postal ballot |
Shareholding Pattern
| Category (%) | Mar2022 | Mar2023 | Mar2024 | Mar2025 | Mar2026 |
|---|---|---|---|---|---|
Promoter and promoter group | 32.52 | 27.90 | 0.00 | 0.00 | 0.00 |
FIIs | 0 | 0 | 0 | 0 | 0 |
DIIs / mutual funds | 0 | 0 | 0 | 0 | 0 |
Public (all non-institutional) | 67.48 | 72.10 | 100.00 | 100.00 | 100.00 |
Number of shareholders | 2,399 | 2,330 | 2,069 | 18,654 | 42,658 |
Major Shareholders
| Holder | Mar 2025 % | Latest disclosed % | Source |
|---|---|---|---|
Skybridge Incap Advisory LLP | 19.47 | 16.89 (Mar 2026) | Tijori; MarketsMojo |
Avance Ventures Private Limited | 15.29 | 9.12 (Mar 2026) | Vogue Stock (BSE pattern); Tijori |
V Cats Consultancy LLP | 13.42 | 13.42 (Sep 2025; later not separately listed) | Tijori |
Send Grid Consultancy LLP | — | 4.62 (date per Simply Wall St) | Simply Wall St |
Slesha Commercial Limited | — | 4.39 | Simply Wall St |
Moonlight Multitrade LLP | — | 4.35 | Simply Wall St |
Tvisha Corporate Advisors LLP | — | 4.12 | Simply Wall St |
Anju Shah | — | 3.29 | Simply Wall St |
Deepak Kharwad | — | 3.08 | Simply Wall St |
Sarvagay Textile LLP | — | 2.44 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Category | Named competitors | Relative positioning |
|---|---|---|
Ayurvedic / herbal OTC tablets and supplements | Dabur India, Himalaya Wellness (private), Patanjali Ayurved (private) / Patanjali Foods (listed), Zandu (Emami), Baidyanath (private), Charak (private) | Incumbents with national distribution, pharmacy reach and decades of brand equity; Aayush is sub-scale |
Nutraceuticals / supplements (D2C, gummies) | HealthKart (MuscleBlaze/HK Vitals, private), Power Gummies (private), Kapiva (private), OZiva (Reckitt), Wellbeing Nutrition (private), Amway India, Herbalife India | Venture-funded D2C brands with heavy marketing spend; Aayush lacks comparable marketing budgets |
Consumer wellness (listed) | Zydus Wellness (Q3 FY2026 net sales up 113.7%, partly acquisition-led, per Indian Pharma Post) | Large listed benchmark for wellness brands |
Mouth freshener / herbal pan masala | Pass Pass (DS Group), Rajnigandha (tobacco-free pan masala, DS Group), Vimal / other regional brands | Dominated by large private groups; regulation-sensitive category |
Diagnostics / preventive health services | Dr Lal PathLabs (launched "Sovaaka" wellness centre), Metropolis Healthcare, Thyrocare, Redcliffe Labs (private), Tata 1mg Labs | Aayush Labs is a startup-scale entrant with no disclosed footprint |
Health kiosks / telemedicine | e-Sanjeevani (government), Practo, Tata 1mg, Apollo 24/7 | Aayush has one disclosed centre |
Peer Comparison FY2026
| Metric | Aayush Wellness | Kaveri Seed | GRM Overseas | Chaman Lal Setia | Sarveshwar Foods |
|---|---|---|---|---|---|
Market cap (INR Cr) | 117 | 3,684 | 1,613 | 1,396 | 430 |
Revenue TTM (INR Cr) | 166 | 1,279 | 1,869 | 1,478 | 1,402 |
Net profit (INR Cr) | 4.24 | 248.50 | 78.36 | 125.12 | 33.01 |
Net margin (%) | 2.52 | 19.09 | 4.13 | 8.40 | 2.34 |
ROE (%) | 37.04 | 14.05 | 14.22 | 15.66 | 7.01 |
P/E (x) | 27.6 | 14.8 | 21.1 | 11.2 | 13.0 |
P/B (x) | 8.6 | 1.8 | 2.6 | 1.8 | 0.9 |
Competitor Detail
| Metric | Aayush Wellness |
|---|---|
Revenue FY2026 (INR Cr) | 155.5 |
Revenue growth FY2026 (%) | 112 |
EBITDA margin FY2026 (%) | 1.2 |
R&D intensity (%) | Not disclosed (≈0) |



